Literature DB >> 10637470

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

C Rosenfeld1, A List.   

Abstract

To guide development of new clinical strategies, a review of recent investigations in the pathobiology of MDS was performed. Articles were identified through a Medline search. Studies, including reviews, are cited in the references. A multistep pathogenesis is proposed. (1) Targeted injury or mutation within hemopoietic stem cells may be followed by an immunologic response adversely affecting progenitor survival. (2) Accelerated proliferation and premature death of marrow cells is amplified by apoptogenic cytokines (TNF-alpha, Fas ligand). (3) Establishment of an abnormal clone associated with telomere shortening. (4) Disease progression associated with loss of tumor suppressor activity. Opportunities for therapeutic interventions are possible at each step. Comparisons between the proposed pathogenesis of MDS and severe aplastic anemia (SAA) are also presented. Leukemia (2000) 14, 2-8.

Entities:  

Mesh:

Year:  2000        PMID: 10637470     DOI: 10.1038/sj.leu.2401618

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

1.  Enhanced growth of myelodysplastic colonies in hypoxic conditions.

Authors:  James Edwin Thompson; Joseph Patrick Conlon; Xiaowei Yang; Patricia Vanessa Sanchez; Martin Carroll
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

Review 2.  New agents in myelodysplastic syndromes.

Authors:  Elias Jabbour; Francis J Giles
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

3.  Inflammatory reactive oxygen species-mediated hemopoietic suppression in Fancc-deficient mice.

Authors:  Daniel P Sejas; Reena Rani; Yuhui Qiu; Xiaoling Zhang; Sara R Fagerlie; Hiroyasu Nakano; David A Williams; Qishen Pang
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

Review 4.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

5.  Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia.

Authors:  Christian R Geest; Miranda Buitenhuis; Edo Vellenga; Paul J Coffer
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

Review 6.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Authors:  Daniella B Kerbauy; H Joachim Deeg
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

Review 7.  Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?

Authors:  Sebastian Stintzing; Ralf Kemmerling; Tobias Kiesslich; Beate Alinger; Matthias Ocker; Daniel Neureiter
Journal:  J Biomed Biotechnol       Date:  2011-05-15

Review 8.  Farnesyltransferase inhibitors in myelodysplastic syndrome.

Authors:  E J Feldman
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 4.213

Review 9.  Small Non-Coding RNAs in Leukemia.

Authors:  Veronica Balatti; Carlo M Croce
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

10.  Myelodysplastic syndrome with erythroid aplasia following pure red cell aplasia.

Authors:  Hyoung Doo Kim; Kee Won Kim; Suk Young Park; Hyeok Jae Ko; Young Yong An; So Young Shin; Ji Young Jang
Journal:  Korean J Intern Med       Date:  2004-09       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.